ONCE - Spark Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Spark Therapeutics's activity chart (see below) currently has 117 price targets and 89 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 96.33% with an average time for these price targets to be met of 191.81 days.

Most recent stock forecast was given by from TD COWEN on 25-Mar-2019. First documented stock forecast 24-Feb-2015.

Best performing analysts who are covering ONCE - Spark Therapeutics:

Elemer Piros Edward Nash Phil Nadeau Mohit Bansal Salveen Richter

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 24-Feb-2015

$80

7 years 5 months 20 days ago
(25-Mar-2019)

5/5 (100%)

$23.99 (42.83%)

375

Buy Since 25-Mar-2019

$74

$-39.57 (-34.84%)

7 years 5 months 20 days ago
(25-Mar-2019)

6/7 (85.71%)

$-39.53 (-34.82%)

203

Buy Since 02-Aug-2017

$65

$-48.57 (-42.77%)

$65

7 years 6 months 18 days ago
(27-Feb-2019)

8/9 (88.89%)

$-48.4 (-42.68%)

179

Buy Since 12-Jul-2016

$72

7 years 6 months 19 days ago
(26-Feb-2019)

6/6 (100%)

$16.24 (29.12%)

280

Buy Since 13-Feb-2018

$114

$0.43 (0.38%)

$62

7 years 6 months 20 days ago
(25-Feb-2019)

4/4 (100%)

$0.52 (0.46%)

103

Show more analysts

Please expand the browser size to see the chart

What is ONCE (Spark Therapeutics) average time for price targets to be met?

On average it took 192 days for the stock forecasts to be reached, with an average price target met ratio of 96.33%.

Which analyst most recently updated their price target on ONCE (Spark Therapeutics)?

Which analyst has the most public recommendations on ONCE (Spark Therapeutics)?

has 0 price targets and 0 ratings on ONCE

Which analyst is the currently most bullish on ONCE (Spark Therapeutics)?

Difei Yang with the highest potential upside of $0.43

Which analyst is the currently most reserved on ONCE (Spark Therapeutics)?

David Nierengarten with the lowest potential downside of -$73.57

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?